White House weighs pulling Heidi Overton's FDA nomination as Senate doubts grow
Trump officials are openly discussing whether to abandon Heidi Overton's FDA commissioner nomination, with Democrats, some Republicans and the Make America Health Again crowd all balking. Her Senate committee vote is set for Nov. 18, and chairman Bill Cassidy says he still has questions.
- Original source: seekingalpha.com.
- The source published it on Nov 16, 2026 at 2:32 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Trump's pick to run the FDA is wobbling. Several key administration officials doubt Heidi Overton can get through the Senate, and they're now talking about dropping her nomination altogether, The Washington Post reports, citing four people familiar with the situation.
The resistance isn't coming from one side. Democrats oppose her, some Republicans do too, and parts of the Make America Health Again camp are unhappy as well, per the Post. Overton currently serves as deputy director of the White House's Domestic Policy Council.
Trump was all-in back in August, calling her "a ROCKSTAR in my administration" when he announced the nomination. That shine has dulled since. On Nov. 13, a group called Health in Office launched a campaign against her, dubbing her "Heidi Vaperton" for what it calls a failure to fight vapes and flavored vapes allegedly marketed to children.
The next test lands Nov. 18, when her nomination goes before the Senate Committee on Health, Education, Labor, and Pensions. Chairman Bill Cassidy (R-La.) told CBS News' "Face The Nation" on Sunday that he still has "questions" about her. The White House hasn't said whether it will pull the nomination before that vote.
TopicsHeidi Overton · FDA · Donald Trump · White House Domestic Policy Council · Senate Committee on Health, Education, Labor, and Pensions · Bill Cassidy · The Washington Post · Health in Office
Source: seekingalpha.com
Written by AI from verified reporting.

